Aclaris Therapeutics, Inc.
ACRS
$4.88
-$0.07-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -69.66M | -64.92M | -141.68M | -134.65M | -130.21M |
| Total Depreciation and Amortization | 428.00K | 454.00K | 495.00K | 564.00K | 692.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.05M | 14.68M | 99.82M | 100.67M | 99.21M |
| Change in Net Operating Assets | 2.98M | 2.67M | -1.56M | 23.43M | 17.99M |
| Cash from Operations | -52.21M | -47.11M | -42.92M | -9.99M | -12.32M |
| Capital Expenditure | -81.00K | -111.00K | -87.00K | -64.00K | -29.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.61M | 48.48M | -50.64M | -61.70M | -67.45M |
| Cash from Investing | -1.69M | 48.37M | -50.73M | -61.76M | -67.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.03M | -- | 80.00M | 80.03M | 80.03M |
| Repurchase of Common Stock | -421.00K | -446.00K | -617.00K | -627.00K | -629.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.42M | -5.42M | -8.13M | -5.09M | -5.09M |
| Cash from Financing | 52.19M | -5.86M | 71.25M | 74.32M | 74.32M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.70M | -4.61M | -22.40M | 2.57M | -5.48M |